利妥昔单抗联合CHOP 方案治疗B 细胞型非霍奇金淋巴瘤的疗效评价

目的评价利妥昔单抗联合CHOP方案治疗B细胞型非霍奇金淋巴瘤的疗效。方法选择我院2006年1月～2006年12月64例B细胞型非霍奇金淋巴瘤患者,随机分为对照组和实验组,每组32例,实验组患者给予利妥昔单抗联合CHOP方案治疗,对照组患者仅给予单纯CHOP方案治疗。治疗后随访6～60个月,通过比较两组患者的治疗有效率,不良反应的发生率以及1年、3年和5年的生存率评价疗效。结果实验组治疗有效率为78.13%,显著高于对照组(50.0%);随访6～60个月后,实验组1、3、5年生存率分别是81.25%、50.0%、12.5%,而对照组1、3、5年生存率分别是68.75%、34.38%、0.0%,实验组1、3、5年生存率均显著高于对照组(P<0.05);两组患者治疗过程中均出现白细胞降低、恶心呕吐、脱发、肝功能损害、贫血的不良反应,但发生率无显著性差异。结论利妥昔单抗联合CHOP方案治疗B细胞型非霍奇金淋巴瘤疗效显著优于单用CHOP方案,且不良反应的发生率没有上升,值得临床进一步的研究和推广。

Evaluation of Therapeutic Effects of Rituximab Combined with CHOP in Treating B-Cell Non-Hodgkin Lymphoma

Objective To evaluate the therapeutic effects of rituximab combined with CHOP on the treatment of B-Cell Non-Hodgkin Lymphoma.Method 64 patients with B-Cell non-Hodgkin lymphoma who were admitted in our hospital from January,2006 to December,2006 were selected and randomly divided into control group and experimental group,32 patients in each group.Patients in the experimental group were treated with rituximab and CHOP,while patients in the control group were only treated with CHOP.The effective rate,incidence of adverse effects,and 1,3,5-year survival rates were compared 6-60 months after treatment.Results The effective rate of the experimental group was 78.13%,significantly higher than that in control group which was 50.0%.6-60 months after treatment,the 1,3,5-year survival rates in experimental group were respectively 81.25%,50.0%,12.5%,all significantly higher than the control group(68.75%,34.38%,and 0.0%).The adverse effects such as leucopenia,nausea and vomiting,alopecia,hypohepatia and anemia were all observed in both groups,but no significant difference of the incidences was observed.Conclusion The treatment of rituximab combined with CHOP had much better therapeutic effect than simplex CHOP,and did not increase the incidences of adverse effects,therefore it was worth of further research and generalization.